title: Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.
abstract: Metabolomic imaging of prostate cancer (PCa) aims to improve in vivo imaging capability so that PCa tumors can be localized noninvasively to guide biopsy and evaluated for aggressiveness prior to prostatectomy, as well as to assess and monitor PCa growth in patients with asymptomatic PCa newly diagnosed by biopsy. Metabolomics studies global variations of metabolites with which malignancy conditions can be evaluated by profiling the entire measurable metabolome, instead of focusing only on certain metabolites or isolated metabolic pathways. At present, PCa metabolomics is mainly studied by magnetic resonance spectroscopy (MRS) and mass spectrometry (MS). With MRS imaging, the anatomic image, obtained from magnetic resonance imaging, is mapped with values of disease condition-specific metabolomic profiles calculated from MRS of each location. For example, imaging of removed whole prostates has demonstrated the ability of metabolomic profiles to differentiate cancerous foci from histologically benign regions. Additionally, MS metabolomic imaging of prostate biopsies has uncovered metabolomic expression patterns that could discriminate between PCa and benign tissue. Metabolomic imaging offers the potential to identify cancer lesions to guide prostate biopsy and evaluate PCa aggressiveness noninvasively in vivo, or ex vivo to increase the power of pathology analysis. Potentially, this imaging ability could be applied not only to PCa, but also to different tissues and organs to evaluate other human malignancies and metabolic diseases.
authors.affiliation: Department of Pathology, Massachusetts General Hospital, Harvard Medical School, CNY-6, 149 13th Street, Charlestown, Boston, MA 02129, USA.
authors.forename: Eva-Margarete
authors.initials: EM
authors.lastname: Spur
authors.forename: Emily A
authors.initials: EA
authors.lastname: Decelle
authors.forename: Leo L
authors.initials: LL
authors.lastname: Cheng
mesh_terms: D006801:Humans; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D013058:Mass Spectrometry; D055442:Metabolome; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism
references.citation: Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31
references.pmid: 15850898
references.citation: N Engl J Med. 2009 Mar 26;360(13):1310-9
references.pmid: 19297565
references.citation: Radiology. 1999 Nov;213(2):473-80
references.pmid: 10551229
references.citation: Cancer Res. 1998 May 1;58(9):1825-32
references.pmid: 9581820
references.citation: Int J Biochem Cell Biol. 2011 Jul;43(7):1002-9
references.pmid: 20633696
references.citation: Lancet. 1983 May 14;1(8333):1059-62
references.pmid: 6133102
references.citation: J Urol. 2004 Apr;171(4):1482-6
references.pmid: 15017203
references.citation: Semin Surg Oncol. 2000 Jan-Feb;18(1):3-9
references.pmid: 10617891
references.citation: J Magn Reson Imaging. 2013 Jun;37(6):1301-25
references.pmid: 23188775
references.citation: Radiology. 1999 Nov;213(2):481-8
references.pmid: 10551230
references.citation: PLoS One. 2011;6(10):e26155
references.pmid: 22022547
references.citation: Magn Reson Med. 2008 Jul;60(1):33-40
references.pmid: 18581409
references.citation: Mol Cancer. 2005 Sep 09;4:32
references.pmid: 16153295
references.citation: Lancet. 1984 Aug 18;2(8399):366-70
references.pmid: 6147452
references.citation: Urol Oncol. 2011 Nov-Dec;29(6):593-601
references.pmid: 20060331
references.citation: J Urol. 2010 Jan;183(1):112-6
references.pmid: 19913814
references.citation: PLoS One. 2011;6(9):e24143
references.pmid: 21915291
references.citation: CA Cancer J Clin. 1999 Sep-Oct;49(5):264-81
references.pmid: 11198954
references.citation: Nat Med. 1995 Oct;1(10):1040-5
references.pmid: 7489360
references.citation: Nature. 2009 Feb 12;457(7231):910-4
references.pmid: 19212411
references.citation: J Natl Cancer Inst. 2012 Jan 18;104(2):125-32
references.pmid: 22228146
references.citation: N Engl J Med. 2009 Mar 26;360(13):1320-8
references.pmid: 19297566
references.citation: J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9
references.pmid: 19720969
references.citation: Radiology. 1996 Mar;198(3):795-805
references.pmid: 8628874
references.citation: Invest Radiol. 2011 May;46(5):301-6
references.pmid: 21217527
references.citation: Magn Reson Med. 2001 Jul;46(1):49-57
references.pmid: 11443710
references.citation: J Proteome Res. 2011 Mar 4;10(3):1361-73
references.pmid: 21166384
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Epilepsy Res. 2010 Feb;88(2-3):127-38
references.pmid: 19926450
references.citation: J Neurol. 2013 Jan;260(1):242-52
references.pmid: 22886061
references.citation: J Psychiatr Res. 2013 Apr;47(4):505-12
references.pmid: 23273650
references.citation: Cancer Res. 2005 Apr 15;65(8):3030-4
references.pmid: 15833828
references.citation: Clin Cancer Res. 2012 Jul 1;18(13):3677-85
references.pmid: 22589396
references.citation: NMR Biomed. 2013 May;26(5):600-6
references.pmid: 23280546
references.citation: Prostate. 2008 Jul 1;68(10):1035-47
references.pmid: 18459103
references.citation: Invest Radiol. 2012 Nov;47(11):624-33
references.pmid: 23011187
references.citation: Prostate. 2010 May 15;70(7):710-7
references.pmid: 20017167
references.citation: BMC Clin Pathol. 2011 Dec 21;11:14
references.pmid: 22188997
references.citation: Prostate. 1999 Feb 1;38(2):166-71
references.pmid: 9973103
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5541-51
references.pmid: 19690195
references.citation: Magn Reson Med. 2003 Nov;50(5):944-54
references.pmid: 14587005
references.citation: Neurology. 2008 Dec 9;71(24):1993-9
references.pmid: 19064881
references.citation: Magn Reson Imaging Clin N Am. 2008 Nov;16(4):697-710, ix-x
references.pmid: 18926432
references.citation: Magn Reson Med. 2005 Jul;54(1):34-42
references.pmid: 15968646
references.citation: Psychiatry Res. 2007 Oct 15;156(1):33-42
references.pmid: 17764911
references.citation: Neurology. 2006 Mar 14;66(5):718-22
references.pmid: 16534109
references.citation: J Magn Reson Imaging. 2012 Sep;36(3):697-703
references.pmid: 22581787
references.citation: Urol Oncol. 2011 Sep-Oct;29(5):572-81
references.pmid: 21930089
references.citation: Sci Transl Med. 2010 Jan 27;2(16):16ra8
references.pmid: 20371475
references.citation: Radiology. 2005 Sep;236(3):903-10
references.pmid: 16118169
references.citation: Magn Reson Med. 2006 Jun;55(6):1257-64
references.pmid: 16685733
references.citation: Prostate Cancer Prostatic Dis. 2012 Sep;15(3):278-82
references.pmid: 22289782
references.citation: Mol Cell Proteomics. 2008 Feb;7(2):411-23
references.pmid: 17991918
references.citation: NMR Biomed. 2009 Jun;22(5):495-501
references.pmid: 19170072
references.citation: Magn Reson Med. 1996 Nov;36(5):653-8
references.pmid: 8916014
references.citation: Curr Opin Urol. 2010 May;20(3):185-8
references.pmid: 20224413
references.citation: Cancer Prev Res (Phila). 2013 Jan;6(1):40-50
references.pmid: 23213071
references.citation: Parkinsonism Relat Disord. 2013 Mar;19(3):329-34
references.pmid: 23238068
references.citation: Radiology. 2005 Mar;234(3):804-14
references.pmid: 15734935
references.citation: Magn Reson Med. 2003 Sep;50(3):627-32
references.pmid: 12939772
references.citation: Anal Bioanal Chem. 2011 Aug;401(2):635-46
references.pmid: 21626193
references.citation: Curr Urol Rep. 2010 May;11(3):165-71
references.pmid: 20425623
references.citation: Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13
references.pmid: 9177231
references.citation: Technol Cancer Res Treat. 2004 Dec;3(6):591-8
references.pmid: 15560717
references.citation: Schizophr Res. 2011 Dec;133(1-3):82-90
references.pmid: 21872444